公开(公告)号：MX2012014049A

公开(公告)日：2013-03-12

申请号：MX2012014049

申请日：2011-06-03

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  LOURY DAVID J ,  MODY TARAK D ,  FYFE GWEN ,  HEDRICK ERIC

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02

Abstract: Se divulgan aquí métodos para tratar un cáncer que comprenden: a. administrar un inhibidor de Btk a un sujeto suficiente para dar como resultado un incremento o aparición en la sangre de una subpoblación de linfocitos definida por inmunofenotipificación; b. determinar el perfil de expresión de uno o más biomarcadores a partir de una o más subpoblaciones de linfocitos; y c. administrar un segundo agente con base en el perfil de expresión determinado.

公开(公告)号：SG186077A1

公开(公告)日：2013-01-30

申请号：SG2012087243

申请日：2011-06-03

Applicant: PHARMACYCLICS INC

Inventor： BUGGY JOSEPH J ,  ELIAS LAURENCE ,  FYFE GWEN ,  HEDRICK ERIC ,  LOURY DAVID J ,  MODY TARAK D

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

公开(公告)号：DE69432221T2

公开(公告)日：2003-12-04

申请号：DE69432221

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER L ,  HARRIMAN M ,  MILLER A ,  MODY TARAK D ,  HEMMI W ,  KRAL A ,  MAGDA DARREN

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00 ,  A61M5/24

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：ES2193163T3

公开(公告)日：2003-11-01

申请号：ES94931812

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  HARRIMAN ANTHONY M ,  MILLER RICHARD A ,  MODY TARAK D ,  HEMMI GREGORY W ,  KRAL VLADIMIR A

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00 ,  A61P35/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：PT745085E

公开(公告)日：2002-10-31

申请号：PT95911776

申请日：1995-02-15

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： SESSLER JONATHAN L ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K31/40 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/00 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrin metal complexes having improved functionalization include the addition of electron-donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron-withdrawing groups to positions 15 and/or 18 of the macrocycle. Electron-donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic pi system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. The addition of substituents to the 12 and 21 positions of the macrocycle offer steric protection for the imine bonds against possible in vivo enzyme hydrolysis. Electron-withdrawing groups at positions 15 and/or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential and imine bond stabilization are useful in a variety of applications.

公开(公告)号：AU727138B2

公开(公告)日：2000-12-07

申请号：AU3226497

申请日：1997-06-04

Applicant: PHARMACYCLICS INC ,  UNIV TEXAS

Inventor： YOUNG STUART W ,  WRIGHT MEREDITH ,  SESSLER JONATHAN L ,  MODY TARAK D ,  MAGDA DARREN

IPC: C07D487/22 ,  A61K9/127 ,  A61K9/50 ,  A61K31/40 ,  A61K31/409 ,  A61K35/18 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00

公开(公告)号：NO985645A

公开(公告)日：1999-02-03

申请号：NO985645

申请日：1998-12-03

Applicant: PHARMACYCLICS INC ,  UNIV TEXAS

Inventor： YOUNG STUART W ,  WRIGHT MEREDITH ,  SESSLER JONATHAN L ,  MODY TARAK D ,  MAGDA DARREN

IPC: C07D487/22 ,  A61K9/127 ,  A61K9/50 ,  A61K31/40 ,  A61K31/409 ,  A61K35/18 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00

CPC classification number: A61K49/1896 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/5068 ,  A61K41/0076 ,  A61K47/554 ,  A61K47/6901 ,  A61K47/6911 ,  A61K49/085

公开(公告)号：SG48392A1

公开(公告)日：1998-04-17

申请号：SG1996009309

申请日：1994-10-12

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： HARRIMAN ANTHONY M ,  HEMMI GREGORY W ,  KRAL VLADIMIR A ,  MAGDA DARREN ,  MILLER RICHARD A ,  MODY TARAK D ,  SESSLER JONATHAN L

IPC: A61K31/40 ,  A61K31/407 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/00 ,  A61K51/04 ,  A61L2/00 ,  A61P35/02 ,  A61P43/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00

Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.

公开(公告)号：NO971317D0

公开(公告)日：1997-03-20

申请号：NO971317

申请日：1997-03-20

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： MAGDA DARREN ,  SESSLER JONATHAN L ,  IVERSON BRENT L ,  SANSOM PETRA I ,  WRIGHT MEREDITH ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: A61K31/70 ,  C12N15/09 ,  A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/04 ,  A61L2/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113

Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.

公开(公告)号：CA2200571A1

公开(公告)日：1996-03-28

申请号：CA2200571

申请日：1995-09-21

Applicant: UNIV TEXAS ,  PHARMACYCLICS INC

Inventor： MAGDA DARREN ,  SESSLER JONATHAN L ,  IVERSON BRENT L ,  SANSOM PETRA I ,  WRIGHT MEREDITH ,  MODY TARAK D ,  HEMMI GREGORY W

IPC: C12N15/09 ,  A61K31/70 ,  A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K49/06 ,  A61K49/08 ,  A61K51/04 ,  A61L2/00 ,  B01J31/06 ,  B01J31/16 ,  B01J31/18 ,  C07D487/22 ,  C07H21/00 ,  C07H21/04 ,  C12N15/113 ,  C07H23/00 ,  C12N13/00 ,  C12N9/16 ,  C12N9/96

Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid, and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.